AI-generated analysis. Always verify with the original filing.
Dianthus Therapeutics, Inc. entered into an underwriting agreement on March 10, 2026, constituting a material definitive agreement. The filing includes the underwriting agreement as Exhibit 1.1.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On March 10, 2026, Dianthus Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting
Financial Statements and Exhibits. (d) Exhibits. EXHIBIT INDEX Exhibit No. Description 1.1 Underwriting Agreement, dated as of March 10, 2026, by and among Dian
Material Agreement